patient with metastatic Ewing's sarcoma who developed encephalopathy after treatment with gemcitabine, and his rapid recovery after discontinuation of the drug. Key Words: Gemcitabine, Neurotoxicity, Pediatric cancer
References
Pavlakis N, Bell DH, Millward MJ, et al. Ratal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291.
Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23: S32-S35.
Gemzar product labeling. Indianapolis, IN, Eli Lilly and Company, March 1997.
Hinchey J, Chaves C, Appignani B, et al. /I reversible posterior leukoencephalopathy syndrome. N Eng! J Med 1996; 334: 494-500.
Ay H, Buonannao F, Schaefer F, et al. Posterior leukoencephalopathy without severe hypertension. Utility of diffusion- weighted MRI. Neurology 1998; 51: 1369- 1376.
Vaughn D, Jarvik J, Hackney D, el al. High- dose cytarabine neurotoxicity. MR findings during the acute phase. Am J Neuroradiol 1993; 14: 1014-1016.
Rontos HA, Wei EP, Deitrich D. Mechanism of cerebral arteriolar abnormalities after acute hypertension. Am J Physiol 1981; 240: 511- 527.
Pavlakis N, Bell DH, Millward MJ, et al. Ratal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291.
Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23: S32-S35.
Gemzar product labeling. Indianapolis, IN, Eli Lilly and Company, March 1997.
Hinchey J, Chaves C, Appignani B, et al. /I reversible posterior leukoencephalopathy syndrome. N Eng! J Med 1996; 334: 494-500.
Ay H, Buonannao F, Schaefer F, et al. Posterior leukoencephalopathy without severe hypertension. Utility of diffusion- weighted MRI. Neurology 1998; 51: 1369- 1376.
Vaughn D, Jarvik J, Hackney D, el al. High- dose cytarabine neurotoxicity. MR findings during the acute phase. Am J Neuroradiol 1993; 14: 1014-1016.
Rontos HA, Wei EP, Deitrich D. Mechanism of cerebral arteriolar abnormalities after acute hypertension. Am J Physiol 1981; 240: 511- 527.
Berrak, S. G., Soysal, A., Türkkan, E., Canpolat, C. (2016). GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Medical Journal, 15(3), 180-182.
AMA
Berrak SG, Soysal A, Türkkan E, Canpolat C. GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Med J. March 2016;15(3):180-182.
Chicago
Berrak, Su Gülsün, Ahmet Soysal, Emine Türkkan, and Cengiz Canpolat. “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”. Marmara Medical Journal 15, no. 3 (March 2016): 180-82.
EndNote
Berrak SG, Soysal A, Türkkan E, Canpolat C (March 1, 2016) GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Medical Journal 15 3 180–182.
IEEE
S. G. Berrak, A. Soysal, E. Türkkan, and C. Canpolat, “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”, Marmara Med J, vol. 15, no. 3, pp. 180–182, 2016.
ISNAD
Berrak, Su Gülsün et al. “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”. Marmara Medical Journal 15/3 (March 2016), 180-182.
JAMA
Berrak SG, Soysal A, Türkkan E, Canpolat C. GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Med J. 2016;15:180–182.
MLA
Berrak, Su Gülsün et al. “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”. Marmara Medical Journal, vol. 15, no. 3, 2016, pp. 180-2.
Vancouver
Berrak SG, Soysal A, Türkkan E, Canpolat C. GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Med J. 2016;15(3):180-2.